Application of PMX-53 polypeptide in preparation of medicine for treating non-alcoholic steatohepatitis

Abstract

The invention discloses an application of a PMX-53 polypeptide in preparation of a medicine for treating non-alcoholic steatohepatitis. After the PMX-53 inhibitor is used for treatment, Hamp is converted from Hamp to Hamp; e and oil red O staining patterns show that the number of lipid droplets in hepatocytes of NASH mice is reduced, the lipid droplets become small, and liver fat is obviously reduced (Figure 3A); quantitative PCR results show that expression of fat synthesis related genes Srebf1, Acc and Fasn is remarkably reduced (figure 3B), WB is further used for confirmation, and figure 3C results show that fat synthesis related proteins Acc and Fasn in mouse liver tissues are reduced; quantitative PCR (Polymerase Chain Reaction) and ELISA (Enzyme-Linked Immunosorbent Assay) detection show that the expression of the inflammation-related factors IL-6 and TNF-alpha is obviously reduced ( The results show that the non-alcoholic steatohepatitis of mice can be relieved by treating with the C5ar1 specific inhibitor PMX-53, so that the PMX-53 can be applied to preparation of the medicine for treating the non-alcoholic steatohepatitis.

Description

Technical field: [0001] The invention belongs to the field of medicine, and in particular relates to the application of PMX-53 polypeptide in the preparation of medicines for treating nonalcoholic steatohepatitis. Background technique: [0002] Nonalcoholic fatty liver disease (NAFLD) is a type of liver disease that excludes alcohol and viruses. NASH), liver fibrosis, cirrhosis, and even clinical syndromes of hepatocellular carcinoma. In recent years, with changes in people's lifestyles and eating habits, the incidence of NAFLD in my country has been increasing year by year, and it has become the second most common chronic liver disease. NASH is the key pathological type of NAFLD, which can progress to liver cirrhosis and liver cancer with poor prognosis. At present, the pathogenesis of NASH has not been fully elucidated, and there is a lack of effective therapeutic drugs. [0003] PMX-53, molecular formula C 47 h 65 N 11 o 7 , the peptide chain fragment is Ac-Phe-cyc...

AI Technical Summary

Problems solved by technology

[0003] PMX-53, molecular formula C 47 h 65 N 11 o 7 , the peptide chain fragment is Ac-Phe-cyclo (Orn-Pro-D-Cha-Trp-Arg), which has anti-inflammatory, anti-cancer and neuron-protective effects, but the therapeutic effect in NASH has not been reported

Images